Skip to Content

Hartford Healthcare R3 HGHRX

Analyst rating as of
NAV / 1-Day Return
41.42  /  1.69 %
Total Assets
1.6 Bil
Adj. Expense Ratio
1.600%
Expense Ratio
1.600%
Fee Level
Above Average
Longest Manager Tenure
20.84 years
Category
Health
Investment Style
Large Growth
Min. Initial Investment
0
Status
Open
TTM Yield
0.00%
Turnover
49%
Premium

Morningstar’s Analysis

Will HGHRX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Not quite as attractive after a longtime manager leaves in mid-2021.

Senior Analyst

Summary

| |

Hartford Healthcare’s team won’t be quite as strong after an upcoming manager departure, so its People rating has been lowered to Above Average from High, and the Morningstar Analyst Ratings of all its share classes have been downgraded to Bronze as a result.

Unlock our full analysis with Morningstar Premium